Post P N, Damhuis R A, van der Meyden A P
Eindhoven Cancer Registry, The Netherlands.
Eur J Cancer. 1998 Dec;34(14 Spec No):2226-31. doi: 10.1016/s0959-8049(98)00320-7.
Since the incidence of prostate cancer has increased considerably over the past two decades in most European countries, knowledge of the variation in survival is pertinent. The collaboration across Europe in the EUROCARE study has now been extended to 45 registries in 17 countries. We report on variation in relative survival according to age of 65,728 patients diagnosed with prostate cancer between 1985 and 1989 and also explore time trends since 1978 for most countries. Considerable variation in survival was found within and between countries, with the highest survival in Switzerland (5-year relative survival 72%), followed by Germany (67%) and the Nordic countries (except Denmark). The lowest survival was found in Estonia (39%), preceded by Slovenia (40%), Denmark (41%) and England (45%). Between 1978 and 1986, relative survival barely changed over time, but it improved from 55% (95% confidence interval [CI] 53-57) during 1984-1986 to 59% (CI 56-61) during 1987-1989. A small but unexpected deterioration of survival for patients aged between 45 and 54 years from 61% to 56% was observed in the early 1980s. It is likely that variation in both detection methods and treatment plays a role in the observed variation in survival, but more information is needed to assess each contribution.
由于在过去二十年中，大多数欧洲国家前列腺癌的发病率大幅上升，了解生存率的差异很有必要。欧洲癌症和治疗结果研究（EUROCARE）中的欧洲合作现已扩展到17个国家的45个登记处。我们报告了1985年至1989年间确诊的65728例前列腺癌患者按年龄划分的相对生存率差异，并探讨了大多数国家自1978年以来的时间趋势。在国家内部和国家之间都发现了生存率的显著差异，瑞士的生存率最高（5年相对生存率72%），其次是德国（67%）和北欧国家（丹麦除外）。爱沙尼亚的生存率最低（39%），其次是斯洛文尼亚（40%）、丹麦（41%）和英国（45%）。1978年至1986年间，相对生存率随时间几乎没有变化，但从1984 - 1986年期间的55%（95%置信区间[CI] 53 - 57）提高到了1987 - 1989年期间的59%（CI 56 - 61）。在20世纪80年代初，观察到45至54岁患者的生存率出现了小幅度但出乎意料的下降，从61%降至56%。检测方法和治疗的差异可能都在观察到的生存率差异中起作用，但需要更多信息来评估各自的影响。
